Dr. Hamilton on Recent Advances in HER2+ Breast Cancer

In Partnership With:

Partner | Cancer Centers | <b>Sarah Cannon Research Institute at Tennessee Oncology</b>

Erika P. Hamilton, MD, discusses the roles of fam-trastuzumab deruxtecan-nxki and tucatinib in HER2-positive breast cancer.

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the roles of fam-trastuzumab deruxtecan-nxki (Enhertu) and tucatinib (Tukysa) in HER2-positive breast cancer.

 In recent years, trastuzumab deruxtecan and tucatinib have garnered significant interest in the HER2-positive breast cancer space, says Hamilton. 

Trastuzumab deruxtecan is an antibody​-drug conjugate that has distinct characteristics from ado-trastuzumab emtansine (Kadcyla; T-DM1)​, explains Hamilton. 

Conversely, tucatinib is a tyrosine kinase inhibitor, ​Hamilton says. Unlike neratinib (Nerlynx) and lapatinib (Tykerb), tucatinib selectively inhibits the growth of HER2-expressing tumor proteins ​and does not block HER1 or EGFR. 

Ultimately, tucatinib is associated with less rash ​and diarrhea ​compared with neratinib and lapatinib. Moreover, tucatinib has demonstrated impressive activity in treating patients with brain metastases, Hamilton concludes.